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Abstract
Background: Missense pharmacogenomic (PGx) variants refer to amino acid substitutions that potentially affect
the pharmacokinetic (PK) or pharmacodynamic (PD) response to drug therapies. The PGx variants, as compared to
disease-associated variants, have not been investigated as deeply. The ability to computationally predict future PGx
variants is desirable; however, it is not clear what data sets should be used or what features are beneficial to this
end. Hence we carried out a comparative characterization of PGx variants with annotated neutral and disease
variants from UniProt, to test the predictive power of sequence conservation and structural information in
discriminating these three groups.
Results: 126 PGx variants of high quality from PharmGKB were selected and two data sets were created: one set
contained 416 variants with structural and sequence information, and, the other set contained 1,265 variants with
sequence information only. In terms of sequence conservation, PGx variants are more conserved than neutral
variants and much less conserved than disease variants. A weighted random forest was used to strike a more
balanced classification for PGx variants. Generally structural features are helpful in discriminating PGx variant from
the other two groups, but still classification of PGx from neutral polymorphisms is much less effective than
between disease and neutral variants.
Conclusions: We found that PGx variants are much more similar to neutral variants than to disease variants in the
feature space consisting of residue conservation, neighboring residue conservation, number of neighbors, and
protein solvent accessibility. Such similarity poses great difficulty in the classification of PGx variants and
polymorphisms.
Background
In humans missense variants that introduce amino acid
substitutions in proteins have received extensive study
as the rich knowledge we have accumulated on protein
function and structure greatly facilitates such investiga-
tion. One intensive research area in this field currently
focuses on identifying and annotating variants asso-
ciated with important functional or phenotypic conse-
quences [1,2]. In the latter, particularly for disease
variant prediction, numerous powerful predictive tools
using a variety of feature sets have been proposed. For
instance, SIFT [3] largely explored sequence conserva-
tion information, PolyPhen2 [4] used physicochemical
and crystal structure properties, SNPs&GO included
functional information [5], and MutPred [6] integrated
a comprehensive list of changes derived from protein
sequence. These tools all operate similarly, a classifica-
tion model based on two curated data sets, e.g., disease
and neutral variant data (the latter being usually
referred as polymorphism) is constructed, or alterna-
tively, from functional and non-functional variant data.
Compared with the many efforts invested in predicting
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,
disease variants [7], the prediction of missense PGx var-
iants by similar approaches has not been studied nearly
as thoroughly.
PGx variants may affect one’s response to a drug
through influencing either PK or PD machinery. The clini-
cal procedure for identifying PGx variants usually involves
measuring drug concentration and several response para-
meters within a cohort, such as blood pressure or body
temperature, during a period of time [8]. Also PGx var-
iants can be identified from GWAS studies or through
candidate gene approaches in large retrospective cohorts.
However these approaches are either time-consuming or
resource-intensive, and computational alternatives are
highly valuable and may aid in characterization of whole
genome sequence interpretation [9]. An attempt to build a
counterpart to MutPred in making missense PGx variant
prediction revealed two issues.
The first issue revolves around the usefulness of the
recognized features that have proven to be beneficial in
disease-neutral variant classification. One of the salient
distinctions between disease and neutral variants is that
disease variants generally occur on much conserved sites
whereas the positions of neutral variants lack such
restriction [3,10]. Therefore, it is not a surprise to see
that protein sequence conservation serves as the most
important single feature in discriminating disease var-
iants from neutral ones [6]. Additionally, structural infor-
mation, especially conservation of neighboring residues
in 3D protein structures, has been demonstrated to be
very useful in classifying catalytic residues [11,12] and
other functional sites [13,14]. Unlike disease or other
functional variants, PGx variants have undergone much
less selective pressure as the corresponding evolutionary
environment–modern medicine–is relatively recent.
Hence, PGx variants may not possess the same strong
sequence conservation patterns as disease variants do.
The second issue is that it is not clear about what var-
iants may constitute a biologically sound non-PGx
group. The selection of the negative set is potentially
affected by the presence of functional variants among
the polymorphisms [15]. The most prominent data
repository for PGx variants is PharmGKB (The Pharma-
cogenomics Knowledgebase; http://www.pharmgkb.org)
[16] which has curated about 5,000 variants from more
than 900 genes. Only a small portion of these variants is
missense. The relatively small coverage of PharmGKB
suggests that available PGx variants are less representa-
tive and many variants outside PharmGKB at present
may exhibit PGx effect in the future studies.
To address the above issues, we collected a set of high-
quality and likely causative PGx variants from PharmGKB




We applied a rigorous process to search for high-quality
and likely causative PGx variants in PharmGKB (see
Methods), and identified 55 PD and 71 PK missense var-
iants with high confidence. Due to the small size of these
two variant sets, we merged them into one group to
increase statistical power in the analysis. One important
issue in the classification of functional variants is the
selection of an accurate negative set of non-functional
ones. At the moment there is no common practice to
address this issue. Thus, in this work we consider all the
variants annotated in UniProt [17] as “Polymorphism”
are functionally neutral. Accordingly, in the rest of the
paper we use the word neutral to represent the missense
variants annotated in UniProt as “Polymorphism”.
In our analysis, we used a dataset composed by 126
PGx variants located in 64 proteins, from which we
also selected additional 487 polymorphisms and 652
disease variants annotated in UniProt database (version
2013_09). It is noteworthy that 104 (83%) of the PGx var-
iants are labeled as polymorphism in UniProt, suggesting
that an annotation of Polymorphism does not necessarily
mean not pharmacogenetic. On the other hand, 11 PGx
variants from current data are labeled as disease in the
same database, suggesting some overlap between disease
and PGx variants. We excluded these overlapped variants
from neutral and disease variant sets, respectively. The
64 proteins belong to 35 superfamilies and we further
grouped them into six classes based on their annotations
(Table 1). PGx variants differ from disease variants in the
distribution across six protein classes (r = 0.40, Pearson
correlation coefficient) but show a highly similar trend as
neutral variants (r = 0.95). Disease variants are most fre-
quently in channel proteins with a density of 51 variants
per protein, whereas PGx and neutral variants both are
enriched in Cytochrome P450 proteins with much smal-
ler densities (2.7 and 12.5, respectively). Counting num-
ber of proteins, we found that 63 proteins have annotated
neutral variants, while only 15 are associated with disease
variants. Such observation is very similar to what we




Enzyme 22 116 130 34
Transporter 14 165 286 34
Cytochrome P450 11 138 47 30
Receptor 10 39 13 17
Channel 3 18 153 4
Others 4 11 23 7
Total 64 487 652 126
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encountered previously in a much more comprehensive
data set [6]. From annotations in UniProt on amino acid
modifications, we could only identify five variants out of
total 1,265 ones with annotated phosphorylation or
methylation sites. As such a sparse coverage presents
very limited variance among variants, functional annota-
tions were excluded from further analysis.
Feature generation from protein structure and sequence
Sequence conservation has been shown to be powerful in
discrimination of disease and neutral variants [3,10,18-20].
Here, we measured sequence conservation for each amino
acid site by calculating a normalized evolutionary rate
from a global multiple species alignment in UCSC genome
browser [21]. Because an earlier version of such data had
been successfully explored in concentrating on benign
with damaging missense variants [10], we followed this
approach but used the Rate4Site tool [22] for higher accu-
racy of conservation estimation. Through searching the
Protein Data Bank (PDB) [23], we identified 31 proteins
with X-ray structures that covered a total of 416 variants
(187 neutral, 174 disease, and 55 PGx). The following fea-
tures based on sequence conservation and protein struc-
ture were derived for 416 variants: average conservation
scores of neighboring residues in 3D, number of neigh-
bors, accessibility, and secondary structure. Other features,
which could be generated from sequence, include pre-
dicted B-value, protein stability, hydrophobic property,
and change in molecular weight, where B-value is a nor-
malized B-factor of C-a of each residue and reflects the
structural flexibility around it [24]. Two sets of variants
were created: a structure data set with 416 variants and
10 features, and a sequence data set with 1,265 variants
and six features (see Additional files 1 and 2 respectively).
Feature difference among three groups of variants
Table 2 shows the comparison between the distribution of
each feature across three groups of variants, e.g., neutral,
disease, and PGx by the Kendall correlation test (a non-
parametric statistical method for measuring monotonic
relationship between two quantities). Compared to the
PGx variants, disease variants occur at the most conserved
positions while neutral variants at less conserved ones
(Figure 1A). One possible explanation for this observation
is that PGx variants were exposed to the environment of
drug therapies relatively recently in the evolutionary time-
frame and thus have undergone little or very mild selective
pressure. Similarly, disease variants have the most con-
served neighbors and are located in the most crowded
environment, and neutral variants display no conservation
in neighborhood in 3D. In contrast, PGx variants stand in
the middle on both measures (Figure 1B). Interestingly,
disease variants tend to be less solvent exposed than PGx
and neutral variants. Such a reverse relationship between
the number of neighbors in 3D structure and solvent
accessibility may be due to that a residue with more neigh-
bors around it provides less space for solvent molecules to
approach. There were no significant associations between
variant groups and B-value, protein stability, hydrophobic
property, or change in molecular weight. At the sequence
level, only conservation displayed significant difference
among the three groups of variants and the same gradient
trend observed in the structure data set was maintained.
Three-group discrimination
A random forest was used to evaluate discrimination of
neutral, disease, and PGx variants. By assigning larger
weights to the minority groups, the classification algorithm
was able to achieve more balanced overall accuracy [25].
In the three-group discrimination, we specified group
weight approximating the reciprocal of corresponding data
size. In the structure data set, an overall error rate of 42%,
with 43% in neutral group, 34% in disease group, and 60%
in PGx group was observed. Thus, PGx variants are
slightly more likely to be misclassified as neutral than as
disease (Figure 2A). When we increased the weight on
PGx group to increase their penalty on misclassification in
random forest, we found a larger increase in the error rate
in neutral variants but less in disease variants with the
decreasing error rate in PGx variants. This challenge high-
lights that PGx and neutral variants are mostly overlapped
in the given feature space and the differences in conserva-
tion, neighbors, and other features are not large enough to
provide sufficient classification power for them. In the
sequence data, the discrimination was even less successful,
although we got triple the data points of the structure data
set (Figure 2B).
Two-group discrimination
As multi-class classification is generally more difficult than
two-class classification, we turned to two-group discrimi-
nation to see whether a clearer boundary among neutral,
disease, and PGx variants could be observed. Table 3
Table 2 Features showing different distribution among
three groups of variant.
Data set Feature Variant τ P-value
Disease PGx Neutral
Structure Conservation -0.474 0.000 0.209 -0.22 6.1 × 10-9
ConsNG -0.316 -0.152 -0.021 -0.21 7.6 × 10-8
NNG 10.0 9.4 8.3 0.18 4.8 × 10-6
ACC 30.4 42.0 52.8 -0.17 1.2 × 10-5
Sequence Conservation -0.323 0.145 0.340 -0.23 7.4 × 10-25
Abbreviations: Conservation, conservation at the variant position; ConsNG,
average conservation of 3D neighbors; NNG, number of 3D neighbors; ACC,
accessibility in number of water molecules; τ, Kendall correlation coefficient. P-
value is computed from Kendall correlation coefficient test. The Kendall test
has been performed sorting the feature vector according their average values
in each class (Disease, PGx and Neutral).
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illustrates that by using a similar weighting strategy to that
of the three-group discrimination, a more accurate classifi-
cation in both disease-neutral and PGx-disease tasks was
observed, with slightly improved performance from
structure data than from sequence data. Once again, the
inferior performance observed in PGx-neutral classifica-
tion signifies more than moderate similarity between
them. If we use any of the prediction accuracy measures
Figure 2 Spread of three types of variant in the neutral-disease plane. Dashed lines constitute the prediction decision boundary among
three types of variant in the neutral (x)-disease (y) plane. The intersections in both figures have a coordinate (1/3, 1/3). The decision boundary
consists of three lines: y - x = 0, 1 - 2x - y = 0, and 1 - x - 2y = 0. (A) Distribution of three groups of variants based on structural data. (B)
Distribution of three groups of variants based on sequence data.
Figure 1 Comparison of conservation scores and accessibility among disease, neutral, and PGx variants. In each box-and-whisker plot,
the black lines denote medians, boxes with gray background cover from the first to third quantile, and notches connecting to the boxes with
dashed lines cover close to 95% interval. (A) Disease variants show strongest conservation and fall within a narrow score range; PGx variants are
less conservative and the scores disperse in a larger range but less broad than neutral variants do. (B) Accessibility is measured by the number
of water molecules. Disease variants are the least accessible, and the accessibility distribution of PGx variants is more similar to that of disease
variants than to neutral ones, which scatter in a significantly larger range.
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as an indicator of the similarity between data sets, then we
find PGx variants stand between neutral and disease
variants.
Allele frequency of three groups of variants
In addition to interspecies conservation, another way of
assessing evolutionary influence on variant sites is
through comparing the minor allele frequency (MAF) of
the variants across representative human populations.
The phase 1 data from the 1000 Genomes Project pro-
vided MAF information for 68,300 missense variants
identified from 1,092 individuals from 14 populations
worldwide [7]. Here we extracted frequency information
for all variants from dbSNP annotations provided by the
1000 Genomes Project. Surprisingly, only 4% disease
variants could find MAF data, indicating that the most
majority of them were not observed in such a global
population sample and hence are likely to be rare in the
whole population. On the other hand, 57% neutral and
74% PGx variants were observed at least once in the
same population sample. Furthermore, the average MAF
of disease variants (0.004) is much lower than either
neutral (0.061, P = 1.6 × 10-3) or PGx variants (0.139,
P = 1.6 × 10-9; Figure 3A). Interestingly, PGx variants
are significantly more frequent than neutral ones (P =
3.5 × 10-9) and it remains to verify whether such a trend
still holds in larger data sets.
Comparison of predicted pathogenesis among three
groups of variants
Although our sequence and structural feature-based ran-
dom forest models are less successful in classifying PGx
and neutral variants than in classifying disease and the
other two groups of variants, it may be informative to
bring in some well-established tools for pathogenesis pre-
diction to this task. We then applied three widely-used
pathogenesis prediction tools, i.e., SIFT [3], PolyPhen2 [4],
and MutPred [6], to all 1,265 variants (see Additional file
3). Unlike PolyPhen2 and MutPred, SIFT outputs for each
non-synonymous variant a score measuring the level of
tolerance and thus a lower score denotes higher probabil-
ity of being pathogenetic (Figure 3B). We observed that
both neutral and PGx variants are significantly less patho-
genetic than disease variants (disease vs. neutral: P = 6.3 ×
10-53; disease vs. PGx: P = 6.7 × 10-13). Both PolyPhen 2
and MutPred generate probability-like score in estimating
how likely a variant is to be pathogenetic, and both tools
show similar score distributions among disease, neutral,
and PGx variants (Figure 3C and Figure 3D), where scores
for disease variants are significantly higher than scores for
either neutral or PGx variants. Across all three tools, the
average score for PGx variants sits between those for neu-
tral and disease variants, and one plausible explanation is
that PGx variants could possess certain weak deleterious
effects compared to neutral variants but these effects are
far less severe than effects of disease variants.
In a similar manner to the random forest models, we
tested how accurate each tool is in classification across
three settings using its predicted scores and recom-
mended threshold. Although all three tools have seen
comparable or better performance in distinguishing dis-
ease variants from either PGx or neutral variants, they
suffered as the random forest models did in discriminat-
ing between PGx and neutral variants (Table 4).
Discussion
From this study PGx variants appear at sites with rela-
tively low sequence conservation and are common in glo-
bal human populations, and their physicochemical
properties resemble those of neutral variants. An appeal-
ing explanation for such observations may be that PGx
variants have come to be under selective pressure very
recently in evolutionary history. The story, however, may
be more complex than this as the finial phenotypic effect
of PGx variants is not as straightforward as that of dis-
ease variants. While typically variants involved in Mende-
lian diseases cause loss of function and manifest narrow
phenotypic spectra, PGx variants have subtler effects on
the PK and PD of drugs. For instance, only 6% of disease
variants in current study have been annotated with more
than one disease, while about half of PGx variants are
related to two or more drugs and their effects depend on
the very drugs and the conditions they target. Another
thread to make things more complex is that the exact
Table 3 Classification performance measurements from two-group comparison (%).
Classification Sensitivity Specificity Accuracy Precision F-measure AUC
Structure
Disease/neutral 76.4 75.4 75.9 74.3 75.4 82.0
PGx/disease 67.3 74.1 70.7 45.1 54.0 78.1
PGx/neutral 58.2 66.3 62.2 33.7 42.7 64.2
Sequence
Disease/neutral 73.5 68.4 70.9 75.7 74.6 79.3
PGx/disease 68.3 72.4 70.3 32.3 43.9 77.4
PGx/neutral 47.6 63.9 55.7 25.4 33.1 56.9
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effects of a PGx variant may largely depend on the drug
dosage and increments in the plasmatic concentration of
the drug resulting from such a variant may have diver-
gent effects.
Imbalanced data are common in biomedical research.
In our data, the ratio of the number of variants from
the most frequent group to the least frequent is 3.4 in
the structure data set and 5.2 in the sequence data set.
Without tuning the classification algorithms, which by
default assume a balanced training set, we observe a
higher error rate in the minority group. Unbalanced per-
formance on the two subsets is due to the higher contri-
bution of the most abundant class to the overall
accuracy. In two-group discrimination, we achieved
approximately balanced sensitivity and specificity across
six classification settings by properly assigning higher
weight to the PGx variant group. The benefit of such
weighting was more noticeable in three-group discrimi-
nation. Without modification to the default random for-
est, the PGx group in the sequence data is almost
Figure 3 Comparison of minor allele frequency and pathogenesis among disease, neutral, and PGx variants . Box-and-whisker
representation of minor allele frequency and pathogenesis among three groups of variants. Note that in (A) not all variants could find MAF data
due to being missing in the 1,092 individuals from the 1000 Genomes Project. (B) SIFT uses a threshold of 0.05 to classify variants with scores
lower than this value as pathogenetic. (C) (D) Both PolyPhen2 and MutPred output probability-like scores measuring pathogenesis of variants.
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completely misclassified, rendering the entire classifica-
tion approach far less sensible.
In current study sequence conservation and structural
information have shown limited capability in discriminat-
ing PGx variants from neutral variants. One approach to
improve classification without a dramatic increase in the
size of the PGx variant dataset might lie in integrating
novel features, such as those derived from 3D structure.
One of such potential alternative features is free energy
change (ΔΔG) caused by a missense variant, which can be
well estimated by FoldX [26] through protein structural
calculations. A recent study in the context of dynamic
pathway analysis found that ΔΔG calculated from FoldX is
directly linked to cell growth and such link can be
expressed in ordinary differential equations accurately
[27]. Thus ΔΔG may serve as an indicator to the potential
influence a variant could cause. Comparing with the classi-
fication of disease and neutral variants, the similar pro-
blem between PGx and neutral variants is less amenable
to otherwise well-established methodologies. While struc-
ture-based features are not as accessible as those derived
from sequences, we did observe that they help improve
the performance of classification slightly. This observation
may in turn suggest that exploring more structure-related
feature might prove to be profitable.
Conclusions
We have determined that PGx variants possess a higher
degree of similarity to neutral genetic polymorphisms than
to disease variants in the feature space consisting of resi-
due conservation, neighboring conservation, number of
neighbors, and accessibility. Such similarity poses a great
difficulty in the classification of PGx and neutral variants.
Future studies focusing on predicting PGx variants may
need a better definition of non-PGx variants or to explore
novel features outside those that have been demonstrated
to be useful in disease-neutral variant classification.
Methods
Data collection
All protein variants annotated as associated with a PGx
trait were extracted from PharmGKB (http://www.
pharmgkb.org). Two investigators then examined each
variant further through curating the original publication
from PharmGKB for a causative relationship between the
variant and PK/PD effects. The selected variants were then
additionally confirmed by PharmGKB scientific curators.
Calculating residue conservation
We downloaded from UCSC genome browser multiple
alignments of 45 vertebrate genomes with Human that
includes amino acid alignment from hg19/GRCh37 RefSeq
genes (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/
multiz46way/alignments/refGene.exonAA.fa.gz) [21]. We
then applied the tool Rate4Site [22] to the multiple protein
sequence alignment to estimate the relative evolutionary
rate for each site, with the supplied phylogenetic tree that
was used to calculate PhastCons scores in UCSC genome
browser at the nucleotide level. The mapping between
RefSeq and UniProt sequences was carried out by the glo-
bal alignment program ggsearch in FASTA [28].
Feature generation
Three-dimensional structures were downloaded from the
PDB [23]. For each protein, we chose the structure with
the largest coverage or the highest resolution if multiple
structures with the same coverage were available, and then
searched for neighboring residues and extracted secondary
structure for each variant based on such structure. To
define the neighboring residues to a given amino acid in a
protein structure we followed the definition of Cilia & Pas-
serini [11]. There every residue is first represented by the
centroid of its side-chain heavy atoms and then any resi-
due falling in a sphere with a radius of eight angstroms
centered on the given residue is defined as a neighbor. For
Table 4 Classification performance measurements from three tools (%).
Classification Sensitivity Specificity Accuracy Precision F-Measure AUC
SIFT
Disease/neutral 71.1 71.1 71.1 75.1 73.1 77.3
PGx/disease 71.1 60.6 65.8 90.3 79.6 70.5
PGx/neutral 54.8
PolyPhen2
Disease/neutral 85.3 57.1 71.2 72.7 78.5 76.9
PGx/disease 85.3 54.0 69.6 90.6 87.8 69.9
PGx/neutral 53.8
MutPred
Disease/neutral 98.5 76.6 87.5 84.9 91.2 95.1
PGx/disease 98.5 61.1 79.8 92.9 95.6 85.9
PGx/neutral 59.1
Classification thresholds between PGx and neutral variants are unknown and thus only AUC was computed for each tool.
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glycine, the alpha-carbon was used as the centroid. Sec-
ondary structure and accessibility (in terms of number of
water molecules) of each variant were directly read from
the output of DSSP [29,30] as applied to the correspond-
ing PDB file. The PDB residue sequences were mapped to
the UniProt sequences as we did in mapping the RefSeq
and UniProt sequences. Protein stability changes due to
variants were estimated by MUpro [31] which estimates
both energy changes and the reliability of underlying
prediction.
Statistical analysis
All computation was carried out in R (www.r-project.
org). The Kendall correlation coefficient and test was
computed by the function cor.test, and Wilcoxon rank
sum test was computed by the function wilcox.test.
Area under the curve (AUC) was calculated through the
R package ROCR [32]. Classification performance mea-
surements are defined below:
Sensitivity = TP/(TP + FN)
Specificity = TN/(TN + FP)
Accuracy = (Sensitivity + Specificity)/2
Precision = TP/(TP + FP)




The source code for implementing the random forest was
obtained from Leo Breiman’s web site (http://www.stat.ber-
keley.edu/~breiman/RandomForests/cc_examples/prog.f)
and compiled as a single program for each experiment
by the GNU Fortran compiler with the following para-
meters: -std=legacy -ffixed-form -ffixed-line-length-none
-fno-range-check. The out-of-bag predictions from each
experimented were weighted internally according to sup-
plied control parameters and normalized to produce pre-
diction scores, which were then used in computing
individual measurements.
Additional material
Additional file 1: Features for the structure data set
Additional file 2: Features for the sequence data set
Additional file 3: MAF and pathogenesis predictions
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